Abstract
Daily administration of 1 mg of folinic acid to immunosuppressed rats with incipient or established Pneumocystis carinii pneumonia did not impair the capacity of trimethoprim-sulfamethoxazole to either prevent or treat this disease. These observations constitute the first experimental support for the use of folinic acid to prevent or control cytopenias that occur in patients with Pneumocystis carinii pneumonia who are under trimethoprim-sulfamethoxazole treatment.
MeSH terms
-
Animals
-
Dexamethasone / analogs & derivatives
-
Dexamethasone / pharmacology
-
Drug Combinations / therapeutic use
-
Drug Interactions
-
Immunosuppression Therapy
-
Leucovorin / therapeutic use*
-
Leukopenia / chemically induced
-
Leukopenia / drug therapy
-
Leukopenia / prevention & control
-
Male
-
Pneumocystis / drug effects
-
Pneumonia, Pneumocystis / complications
-
Pneumonia, Pneumocystis / drug therapy*
-
Pneumonia, Pneumocystis / prevention & control
-
Random Allocation
-
Rats
-
Rats, Inbred Strains
-
Sulfamethoxazole / therapeutic use*
-
Tetracycline / pharmacology
-
Trimethoprim / therapeutic use*
-
Trimethoprim, Sulfamethoxazole Drug Combination
Substances
-
Drug Combinations
-
dexamethasone 21-phosphate
-
Dexamethasone
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Trimethoprim
-
Tetracycline
-
Sulfamethoxazole
-
Leucovorin